Compare Starter Protocols: Wegovy vs Mounjaro Dosing
Wegovy 1mg vs Mounjaro Starter Dose: Understanding the Difference
When comparing Wegovy 1mg vs Mounjaro for your weight management journey, the starter dose approach differs significantly between these two prescription-only medicines. Wegovy follows a gentle 16-week escalation protocol, beginning with 0.25mg weekly for the first month, then progressing through 0.5mg and 1mg doses before reaching maintenance levels. This gradual approach helps minimise potential gastrointestinal side effects whilst allowing your body to adapt to the medication. Mounjaro, conversely, starts at 2.5mg weekly for four weeks before increasing to 5mg, representing a different philosophical approach to dose escalation.
The Wegovy 1mg dose specifically represents weeks 9-12 of your treatment journey, by which point many patients report established appetite regulation and emerging weight management results. At this stage, you're well beyond the initial starter phase and moving towards the higher therapeutic doses. Understanding where 1mg fits within the complete dosing schedule helps explain why you cannot skip directly to this dose without completing the earlier escalation steps, which are essential for both safety and treatment effectiveness.
Wegovy 1mg vs Mounjaro Pricing: Starter Dose Economics
The cost structure for Wegovy 1mg vs Mounjaro starter protocols varies considerably, with Wegovy's 0.25mg starter dose priced at £79.99 compared to the 1mg dose at £99.99. New customers can apply discount code FIRST40 at checkout to reach these final prices, whilst returning patients use code DOSE25. For those beginning their Wegovy journey, our Intro Duo bundle (0.25mg + 0.5mg) at £169.99 provides the first two months of treatment in a single convenient order. This bundle approach ensures continuity of supply without multiple prescription reviews.
Mounjaro pricing follows a different structure due to its distinct dose strengths and escalation protocol. When comparing Wegovy 1mg vs Mounjaro overall costs, consider that Wegovy's maintenance dose of 2.4mg costs £209.99, whilst the complete starter journey from 0.25mg through to 1mg spans three individual doses. Our Progress Duo (0.5mg & 1mg) at £189.99 bridges the gap between early treatment phases, whilst the comprehensive Intro Trio (0.25mg, 0.5mg & 1mg) at £299.99 covers your first three months of dose escalation.
Clinical Evidence: Wegovy 1mg vs Mounjaro Research Findings
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks (Wilding et al., NEJM, 2021). By the time patients reach the 1mg dose during weeks 9-12, many begin experiencing the appetite suppression effects that contribute to these longer-term outcomes. However, it's important to note that individual results may vary significantly, and the medication works as part of a comprehensive lifestyle approach including reduced-calorie diet and increased physical activity.
Mounjaro's clinical evidence comes from the SURMOUNT trial series, showing its dual GIP and GLP-1 receptor agonist mechanism. When evaluating Wegovy 1mg vs Mounjaro effectiveness, both medications have demonstrated significant weight management benefits in their respective clinical programmes, though direct head-to-head comparisons are limited due to different trial designs and patient populations. Your prescriber can help determine which treatment approach aligns better with your individual medical history and weight management goals.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones responsible for blood sugar regulation and appetite control. When you inject Wegovy weekly, it activates GLP-1 receptors in your brain's appetite centres, promoting feelings of satiety and reducing food cravings between meals. The medication also slows gastric emptying, meaning food remains in your stomach longer, contributing to prolonged fullness after smaller portions. This dual mechanism of central appetite suppression and peripheral gastric effects explains why the dose escalation protocol is essential - your body needs time to adapt to these significant changes in hunger and satiety signalling. Unlike Mounjaro's dual GIP and GLP-1 approach, Wegovy focuses specifically on the GLP-1 pathway, which has been extensively studied for weight management applications. The 1mg dose represents a significant step towards the full therapeutic effect whilst maintaining tolerability for most patients.
EverydayMeds Ordering Process: From Assessment to Delivery
Beginning your Wegovy 1mg vs Mounjaro comparison starts with our streamlined 3-minute online clinical assessment, designed to gather essential medical history and weight management goals. Our UK-based prescribers, working within our GPhC-registered pharmacy (#9012878), review your assessment typically within 3 working days, with express 24-hour reviews available for urgent requirements. Once your prescription is approved, we dispatch your medication via next-day delivery using specialist cold-chain packaging to maintain the required 2-8°C temperature throughout transit. This temperature-controlled supply chain ensures your medication arrives in optimal condition, whether you're starting with the 0.25mg starter dose or progressing to the 1mg escalation phase. Our clinical team remains available throughout your treatment journey to address any questions about dose progression, side effect management, or prescription renewals.
Storage and Practical Considerations: Wegovy 1mg vs Mounjaro
Storage requirements present a key practical difference when comparing Wegovy 1mg vs Mounjaro for your weight management routine. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigerated storage, compared to Mounjaro's 21-day room temperature limit. This storage advantage makes Wegovy particularly convenient for frequent travellers or those with limited refrigerator space. Both medications use pre-filled injection pens - Wegovy utilises Novo Nordisk's FlexTouch technology, whilst Mounjaro employs Lilly's KwikPen system. The weekly injection schedule for both treatments means you'll use one pen per month, with the dose escalation requiring different pen strengths rather than dial adjustments. Your 1mg Wegovy pen contains four pre-measured doses, clearly marked for weekly administration, and the escalation protocol prevents skipping directly to this strength without completing the 0.25mg and 0.5mg phases first.
Starter Dose Safety: Why Wegovy 1mg vs Mounjaro Escalation Matters
The fundamental difference between Wegovy 1mg vs Mounjaro starter approaches reflects each medication's unique safety profile and therapeutic development. Wegovy's gradual escalation from 0.25mg allows your digestive system to adapt progressively to GLP-1 receptor activation, significantly reducing the likelihood of severe nausea, vomiting, or diarrhoea that can occur with rapid dose increases. Clinical studies specifically designed the 4-week intervals between dose increases to optimise both tolerability and therapeutic benefit. Attempting to begin treatment at the 1mg level bypasses crucial adaptation periods and substantially increases discontinuation risk due to side effects.
Mounjaro's starting dose of 2.5mg represents its manufacturer's determination of the minimum effective dose for the dual GIP/GLP-1 mechanism, which differs from Wegovy's single-pathway approach. When comparing Wegovy 1mg vs Mounjaro starter safety, both have undergone extensive clinical testing, but the escalation protocols are not interchangeable between medications. Your prescriber will consider your previous experience with GLP-1 treatments, current medications, and gastrointestinal sensitivity when determining the most appropriate starting approach for your individual circumstances.
Making Your Choice: Wegovy 1mg vs Mounjaro Decision Factors
Your decision between Wegovy 1mg vs Mounjaro ultimately depends on several personal and clinical factors beyond the starter dose comparison. Consider your lifestyle requirements, such as travel frequency (favouring Wegovy's longer room temperature stability), injection preference, and tolerance for dose escalation schedules. Some patients prefer Wegovy's slower, more gradual approach to reaching therapeutic doses, whilst others may find Mounjaro's dual mechanism approach more suitable for their metabolic profile. Both medications require commitment to the complete dosing protocol - you cannot skip to the 1mg Wegovy dose without completing the earlier phases, just as you cannot modify Mounjaro's escalation schedule. Your prescriber can help evaluate which medication aligns better with your medical history, current treatments, and weight management objectives. Both Wegovy and Mounjaro are available from EverydayMeds through our comprehensive clinical assessment process, ensuring you receive appropriate prescriber guidance regardless of your choice. Remember that successful weight management with either medication requires ongoing commitment to dietary changes and increased physical activity alongside the prescription treatment.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
